MA55809B1 - Formulations d'anticorps anti-il-6 - Google Patents

Formulations d'anticorps anti-il-6

Info

Publication number
MA55809B1
MA55809B1 MA55809A MA55809A MA55809B1 MA 55809 B1 MA55809 B1 MA 55809B1 MA 55809 A MA55809 A MA 55809A MA 55809 A MA55809 A MA 55809A MA 55809 B1 MA55809 B1 MA 55809B1
Authority
MA
Morocco
Prior art keywords
antibody formulation
antibody formulations
disorders
oxidation
treating
Prior art date
Application number
MA55809A
Other languages
English (en)
Other versions
MA55809A (fr
Inventor
Gaozhong Zhu
Zahra Shahrokh
Mark Melville
Madhav N. DEVALARAJA
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of MA55809A publication Critical patent/MA55809A/fr
Publication of MA55809B1 publication Critical patent/MA55809B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formulations d'anticorps anti-IL-6 aqueuses stables qui ont un niveau de formation d'agrégat et d'oxydation réduit. Les formulations d'anticorps anti-IL-6 sont appropriées pour traiter des maladies et des troubles médiés par IL-6.
MA55809A 2019-05-01 2020-04-30 Formulations d'anticorps anti-il-6 MA55809B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962841662P 2019-05-01 2019-05-01
EP19181345 2019-06-19
EP20728590.9A EP3962942B1 (fr) 2019-05-01 2020-04-30 Formulations d'anticorps anti-il-6
PCT/US2020/030865 WO2020223565A1 (fr) 2019-05-01 2020-04-30 Formulation d'anticorps anti-il-6

Publications (2)

Publication Number Publication Date
MA55809A MA55809A (fr) 2022-03-09
MA55809B1 true MA55809B1 (fr) 2025-12-31

Family

ID=70857238

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55809A MA55809B1 (fr) 2019-05-01 2020-04-30 Formulations d'anticorps anti-il-6

Country Status (8)

Country Link
EP (3) EP4631523A3 (fr)
JP (3) JP7701273B2 (fr)
ES (1) ES3055418T3 (fr)
HR (1) HRP20251529T1 (fr)
MA (1) MA55809B1 (fr)
PL (1) PL3962942T3 (fr)
RS (1) RS67540B1 (fr)
WO (1) WO2020223565A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856135A (en) 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
RU2318829C2 (ru) 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
AU2003261787B2 (en) 2002-08-30 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
CA2749200A1 (fr) 2009-01-29 2010-08-05 Michael Bowen Anticorps humains anti-il-6 a demi-vie prolongee in vivo et leur utilisation en oncologie et pour le traitement de maladies autoimmunes et inflammatoires
EP2399604A1 (fr) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Nouvelle formulation d'anticorps
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN104768578A (zh) * 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
CA3119498A1 (fr) 2015-07-31 2017-02-09 Medimmune Limited Methodes de traitement de troubles medies par l'hepcidine
EP3419599A4 (fr) * 2016-02-23 2019-09-11 Sesen Bio, Inc. Formulations d'antagonistes d'il-6 et leurs utilisations
TWI716668B (zh) 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.

Also Published As

Publication number Publication date
EP4631523A3 (fr) 2025-12-31
ES3055418T3 (en) 2026-02-11
JP2025166156A (ja) 2025-11-05
EP3962942C0 (fr) 2025-10-22
WO2020223565A1 (fr) 2020-11-05
PL3962942T3 (pl) 2026-02-16
EP4591885A2 (fr) 2025-07-30
EP4591885A3 (fr) 2025-11-19
JP7701273B2 (ja) 2025-07-01
JP2025114623A (ja) 2025-08-05
MA55809A (fr) 2022-03-09
EP3962942B1 (fr) 2025-10-22
EP4631523A2 (fr) 2025-10-15
EP3962942A1 (fr) 2022-03-09
JP7755766B2 (ja) 2025-10-16
HRP20251529T1 (hr) 2026-01-16
JP2022531331A (ja) 2022-07-06
RS67540B1 (sr) 2026-01-30

Similar Documents

Publication Publication Date Title
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
EP4272731A3 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
PH12020551716A1 (en) Anti-ror antibody constructs
CR20210500A (es) Anticuerpos de cadena pesada que se unen al psma
PH12023552763A1 (en) Agonistic anti-il-2r antibodies and methods of use
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
ZA201907599B (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2019209965A3 (fr) Protéines de fusion de l'interleukine 12, et compositions et procédés thérapeutiques associés
MX2023002507A (es) Inhibidores de cd73.
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
JOP20220020B1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
EP4603508A3 (fr) Anticorps anti-fzd et méthodes d'utilisation
EP4378536A3 (fr) Inhibiteurs peptidiques oraux du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies intestinales inflammatoires
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2020123773A3 (fr) Anellosomes pour l'administration de modalités thérapeutiques sécrétées
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
ZA202006264B (en) Stable formulations of therapeutic antibody
WO2022183074A3 (fr) Anticorps anti-psma et structures car-t
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EA201791937A1 (ru) Противовоспалительные полипептиды